Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 636

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort Study

Open access
Niederau, Claus, Lange, Stefan, Heintges, Tobias, Erhardt, Andreas, Buschkamp, Marlies, Hürter, Dietmar, Nawrocki, Marek, Kruska, Lothar, Hensel, Frank, Petry, Wolfgang, Häussinger, Dieter·1998·Hepatology

Abstract

The prognosis of chronic hepatitis C virus (HCV) infection is still ill–defined. The present study prospectively evaluated mortality and complications in a large cohort of patients with chronic hepatitis C. The study included 838 anti–HCV and HCV–RNA-positive patients who were followed for 50.2 ± 26.9 months (mean ± SD; range, 6–122 months) in a prospective protocol. During follow–up, 62 patients died (31 from liver disease and 31 from other causes), and 12 patients needed liver transplantation. When compared with a matched general population, hepatitis C increased mortality mainly when cirrhosis was present and in patients who were less than 50 years old at study entry. During follow–up, a further 30 patients developed nonlethal complications of cirrhosis. By multivariate regression, survival was decreased by cirrhosis, long disease duration, history of intravenous drug abuse, and excessive alcohol consumption, whereas interferon therapy improved survival. Alanine transaminase (ALT), bilirubin, sex, and genotype had no effect on survival. The risk of hepatocellular carcinoma (HCC) (n = 17) was increased by cirrhosis and to a lesser degree by long disease duration and high bilirubin, whereas interferon therapy, genotype, and other factors had no effect. Chronic hepatitis C is a disease with considerable mortality and morbidity when cirrhosis is present at diagnosis. Patients who acquire the infection early in life have a markedly increased mortality even when cirrhosis is absent at diagnosis. The age at diagnosis therefore should play a major role in therapeutic considerations. The present data also suggest that interferon therapy has a long–term clinical benefit, although it did not reduce the risk of liver cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510280632

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 636

Metadata

Authors
Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hürter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., & Häussinger, D.
Venue
Hepatology
Published
1998-12
Volume
28
Issue
6
Pages
1687-1695
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2075293916
Cited by
636
References
33
FWCI
23.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort Study. https://app.cochat.ai/papers/10.1002/hep.510280632
The paper
Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hürter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., & Häussinger, D. (1998). Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort Study. Hepatology. https://doi.org/10.1002/hep.510280632

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.